Close Menu

NEW YORK (GenomeWeb) – In line with a recent coverage decision from Palmetto GBA concluding that large syndromic molecular diagnostic panels may not always be medically justifiable, molecular diagnostics manufacturer GenePOC is investing in the development of small syndromic PCR-based panels. The Canadian firm will now push forward on panels with around five targets beginning with tests for carbapenem-resistant enterobacteriaceae (CREs) and gastrointestinal pathogens.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.